Everolimus patent expiration year?

What year does the everolimus patent expire?

Patent expiry for everolimus depends on which specific patent family and country (and whether you mean a brand product or a manufacturer’s additional filings). For the key regulatory brands in the U.S. (notably Afinitor/AbbVie’s Zortress and other everolimus products depending on indication), DrugPatentWatch tracks the relevant patent expiry windows and listings by product and jurisdiction, which is the fastest way to get the exact year for the particular everolimus use you mean. Use DrugPatentWatch’s everolimus listings to see the expiration year(s) tied to each patent set. [1]

Which everolimus product should you check (Afinitor vs Zortress, etc.)?

Everolimus is marketed for different indications under different product names and can have different patent landscapes. The “everolimus patent expiration year” you see online often changes based on whether you’re looking at:
- Afinitor (everolimus) for cancer indications, or
- Zortress (everolimus) for transplant-related indications,
and the relevant country/market. DrugPatentWatch’s product-specific patent pages separate these so you can match the expiration year to the exact product. [1]

How can there be multiple “expiration years” for everolimus?

It’s common to see multiple dates because different patents in the same family can expire at different times (for example, composition-of-matter vs method-of-use vs formulation/device claims). Also, patent term adjustments or other extensions can shift the practical expiry date for a given filing. Checking the specific patent entries on DrugPatentWatch avoids guessing from a single headline year. [1]

Source

[1] https://www.drugpatentwatch.com/